Navigation Links
Experimental vaccine for shingles is effective

Researchers have discovered a newer form of chicken pox vaccine to// effectively control the painful condition called shingles.

Shingles (also known as herpes zoster) is the condition that gets symptoms of rashes or blisters on the skin, along with sensations of burning pain, tingling, and numbness on the area. There may be fever with chills, headache or upset stomach. The infection is somewhat like chicken pox and is caused by the same virus varicella-zoster. Anyone who had chicken pox once is at a risk. Scientists say that the chicken pox virus moves into the nervous system after the attack, and reactivates as shingles.

The new vaccine called zoster vaccine is a more potent version of the chicken pox vaccine that’s available for the children. This vaccine contains live and weak form of the varicella-zoster virus that causes chicken pox. The vaccine had been able to prevent the occurrence of shingles for half the people who received it, and reduced significantly the severity and complications of the disease in most of the vaccinated people.

Shingles is a condition that keeps on affecting people and affects the elderly people more severely. The new vaccine for adults will now be able to bring relief to all people who have been suffering from the disease.

The research will be published in the new edition of New England Journal of Medicine.
'"/>




Page: 1

Related medicine news :

1. Experimental treatment for Ebola Virus Shows promising results in mice
2. Experimental drug to fight flu
3. Experimental SARS Vaccine
4. Experimental Blood Test May Spot Heart Attack Risk, Study Says
5. Five AIDS Patients To Receive Experimental Anti-retroviral Drugs
6. Protection against HIV and Herpes is possible with the Experimental Microbicide
7. Experimental Therapy Effective Against Malignant Melanoma in Horses
8. Experimental Alzheimer’s Drug curbs the disease in mic
9. New Guidelines to Be Laid While Testing Experimental Drugs
10. Experimental Drug Deals Effectively with Prostate Cancer Cells
11. Experimental Drug Causes Cytokine Storm
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/25/2017)... Vegas, NV (PRWEB) , ... April 25, 2017 ... ... can now choose a modern procedure that achieves results in a fraction of ... in Las Vegas, NV, with Significance Dental Specialists, now offers this revolutionary ...
(Date:4/25/2017)... GA (PRWEB) , ... April 25, 2017 , ... ... their neck and back pain with a reputable physician in their area, announces the ... CRM protects patient information for patients who are looking for reputable physicians to help ...
(Date:4/25/2017)... ... April 25, 2017 , ... Somnoware, a ... its patient care management module. Using this new feature, sleep physicians can now ... initiated on continuous positive airway pressure (CPAP), oral, or other forms of sleep ...
(Date:4/25/2017)... ... ... Vetoquinol USA® , a world-class developer of veterinarian-approved ... EQUISTRO line, at this week’s Rolex Kentucky Three-Day Event in Lexington. Flexadin UCII ... The scientifically-developed Flexadin UCII supports the body’s normal repair of cartilage and joints. ...
(Date:4/24/2017)... ... April 24, 2017 , ... LG ... Your Own Device (BYOD) capabilities at Telehealth 2.0, the American Telemedicine Association’s national ... which pairs medical devices with a pre-programmed tablet in a remarkably easy-to-use kit ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... , April 19, 2017 Cardiology devices segment is ... period The Cardiology Devices segment is likely to ... 15 Mn in 2018 over 2017. By the end of ... valuation close to US$ 700 Mn, expanding at a CAGR ... dominated the Asia Pacific reprocessed medical ...
(Date:4/19/2017)... , April 19, 2017  Vanderbilt University Medical ... patients in Nashville , Tennesse have ... Esophageal Sphincter Stimulation for GERD (LESS GERD) trial. The ... provide long-term reflux control by restoring normal function to ... 65 million people in the United States ...
(Date:4/19/2017)... HANOVER, N.J. , April 19, 2017 /PRNewswire/ ... conducted by the National Heart, Lung, and Blood ... (NIH) demonstrating that 58% of patients with treatment-naïve ... six months when treated with eltrombopag at the ... 1 . The study evaluated three sequential treatment ...
Breaking Medicine Technology: